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Efficacy of Levofloxacin and Rifaximin based Quadruple Therapy 
in Helicobacter pylori Associated Gastroduodenal Disease: 
A Double-Blind, Randomized Controlled Trial
The aim of this study was to evaluate the efficacy of levofloxacin and rifaximin based 
quadruple regimen as first-line treatment for Helicobacter pylori infection. A prospectively 
randomized, double-blinded, parallel group, comparative study was performed. Three 
hundred consecutive H. pylori positive patients were randomized to receive: omeprazole, 
amoxicillin, clarithromycin (OAC); omeprazole, amoxicillin, levofloxacin (OAL); and 
omeprazole, amoxicillin, levofloxacin, rifaximin (OAL-R). The eradication rates in the 
intention to treat (ITT) and per protocol (PP) analyses were: OAC, 77.8% and 85.6%; OAL, 
65.3% and 73.6%; and OAL-R, 74.5% and 80.2%. The eradication rate achieved with 
OAC was higher than with OAL on the ITT (P = 0.05) and PP analysis (P = 0.04). OAL-R 
regimen was not inferior to OAC. The frequency of moderate to severe adverse effects was 
significantly higher in OAC treatment group. Especially, diarrhea was most common 
complaint, and there was a significantly low rate of moderate to severe diarrhea with the 
rifaximin containing regimen. In conclusion, the levofloxacin and rifaximin based regimen 
comes up to the standard triple therapy, but has a limited efficacy in a Korean cohort. The 
rifaximin containing regimen has a very high safety profile for H. pylori eradication 
therapy.
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ORIGINAL ARTICLE
Gastroenterology & Hepatology
INTRODUCTION
Helicobacter pylori is a Gram-negative bacteria that colonizes 
the human stomach and plays a major role in peptic ulcer dis-
ease, low-grade mucosa-associated lymphoid tissue lymphoma 
and gastric cancer. Eradication of H. pylori is the recommended 
treatment for these conditions (1). Proton pump inhibitor (PPI) 
based triple therapy, which includes PPI, amoxicillin and clar-
ithromycin/metronidazole is generally accepted as first-line 
therapy (2); however, there has been a substantial decline in the 
H. pylori eradication rates recently. The outcomes of current H. 
pylori eradication regimens have been disappointing (3). The 
reasons for eradication failure are diverse and they include an-
tibiotic resistance, poor compliance, the short duration of ther-
apy, drug-related adverse effects, bacterial load, smoking, and 
underlying disease (4, 5). Among them, antibiotic resistance is 
an important factor in the treatment failure; primary resistance 
to clarithromycin or metronidazole significantly affects the effi-
cacy of eradication therapy (6, 7). 
  Rifaximin is an oral antibiotic that belongs to the rifabutin fam-
ily. It is not absorbed by the gastric and intestinal mucosa and is 
highly concentrated in the gastrointestinal tract. It has a broad-
spectrum of in vitro activity against Gram-positive or Gram-neg-
ative enteric bacteria (8). The minimum inhibitory concentra-
tion (MIC) of rifaximin is comparable to many antibiotics used 
for H. pylori eradication (9, 10). Because it is not absorbed, rifax-
imin has a low risk of causing bacterial resistance. Levofloxacin 
is a fluoroquinolone that exerts broad-spectrum bactericidal 
effects by inhibiting DNA gyrase. It is active against H. pylori in 
vitro and has a synergistic effect with PPIs (11). The currently 
reported efficacy of levofloxacin-based therapy for H. pylori 
eradication ranged from 60% to 90%, in per protocol (PP) anal-
ysis (12, 13). 
  The goal of this study was to determine the efficacy of levoflox-
acin and to evaluate the efficacy of levofloxacin and rifaximin 
based quadruple therapy as first line of treatment for H. pylori 
infection in a Korean cohort. In addition, the combination of rifax-
imin was studied for its synergistic effects for H. pylori eradication. 
MATERIALS AND METHODS 
Patients
A prospectively randomized, double-blinded, parallel group, 
comparative study was performed between July 2008 and Sep-Choi KH, et al.  •  Levofloxacin and Rifaximin Based Quadruple Therapy 
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tember 2009 at St. Vincent’s Hospital, the Catholic University of 
Korea, Suwon.
  All patients referred to the endoscopy unit were recruited for 
this prospective study. They were eligible to enter the study if 
they were older than 18 yr of age and had gastric H. pylori infec-
tion. The diagnosis of H. pylori infection was made based on 1) 
positive rapid urease test (CLOtest; Delta West, Bentley, Austra-
lia) or 2) histologic evidence of H. pylori in any of two specimens 
taken from antrum/corpus by silver stain. Patients were not per-
mitted to take H2 receptor antagonists or any other ulcer healing 
drugs during the study period. None of the patients had a histo-
ry of H. pylori eradication, previous gastric surgery or had taken 
antibiotics in the two months before the study. Patients were also 
excluded if they had significant renal, hepatic, cardiovascular, 
metabolic or hematological disorders. Additionally, pregnant 
or lactating women were excluded from our investigation.
 
Sample size
An estimated sample size of 88 subjects per group would give 
an 80% power to detect a difference of 15% for the eradication 
rate in the levofloxacin-based therapy compared to the standard 
triple therapy (assumed to have an eradication rate of 80%), with 
a two-sided alpha = 0.05. With a 10% drop out rate we have to 
recruit at least 97 patients for each group. 
Randomization
All patients were randomized to receive one of the three first-line 
treatment regimens, all given for seven days. Randomization 
codes (A, B, C) were packed into sealed opaque envelopes by 
an individual not involved in screening and enrolment of sub-
jects to ensure concealment of allocation. One pharmacist had 
a responsibility for dispensing the trial drugs to the patient based 
on the unique randomization code. The trial drugs were labelled 
by the manufacturer (A-1 to A-100, B-1 to B-100, C-1 to C-100). 
At the end of allocation, the pharmacist provided us with a ran-
domization list. 
Eradication of H. pylori
Each group contained 100 eligible patients and received a differ-
ent treatment regimen. Patients in group 1 received omeprazole 
20 mg, clarithromycin 500 mg and amoxicillin 1.0 g, twice a day 
for 7 days (OCA); in group 2, omeprazole 20 mg, amoxicillin 1.0 
g and levofloxacin 200 mg, twice a day for 7 days (OAL); and in 
group 3, omeprazole 20 mg, amoxicillin 1.0 g, levofloxacin 200 
mg and rifaximin 400 mg, twice a day for 7 days (OAL-R). No 
further treatment was given, and instructions about adherence 
to treatment were given to each patient.
13C-urea breath test (UBT)
Eradication of H. pylori was assessed by the 
13C-UBT at six weeks 
after completion of treatment. Proton pump inhibitors and an-
timicrobial agents that might affect the 
13C-UBT were not given 
to the patients after completion of therapy. The 
13C-UBT was 
performed with a capsule-based modification. In brief, the pa-
tients fasted for over 12 hr before examination and then a gela-
tin capsule containing 38 mg 
13C-urea was ingested with 50 mL 
water. Breath samples before and 20 min after administration 
of 
13C-urea were collected after a mouthwash. The 
13C/
12C ratio 
in the breath samples was measured by mass spectrometry (He-
liview; MediChems, Seoul, Korea). The changes in the 
13C value 
over the baseline were expressed as Δ
13C. A positive result was 
defined as an increase of > 2‰. 
Analysis
The eradication rate was evaluated for each drug regimen by the 
per-protocol (PP) analysis based on the number of patients that 
completed the study, and by an intention-to-treat (ITT) analy-
sis that took into account all of the patients, including those who 
dropped out because of severe adverse effects, those who had 
poor drug compliance, and those who were lost to follow-up. The 
patients were interviewed during their first visit to the clinic after 
completion of therapy to clarify their compliance with the ther-
apy and identify any adverse effects. Poor compliance was de-
fined as taking less than 90% of the total medication prescribed. 
Evaluation of adverse effects
The questionnaire contained questions regarding personal his-
tory of smoking and alcohol drinking. Smokers were those who 
consumed more than one pack of cigarettes a week and drink-
ers were those who drank more than one cup of alcoholic bev-
erage a day. All “adverse effects” were assessed by the question-
naire. The adverse events included anorexia, nausea, taste dis-
turbance, dizziness, abdominal pain, diarrhea, headache, and 
skin eruption. For the purpose of analyses, adverse effects was 
considered as a binomial variable (present-absent) and scored 
as mild, moderate or severe according to their influence on the 
daily activities of living.
Statistics
All data were recorded on standard forms and computer ana-
lyzed. The Student t-test was used to compare continuous vari-
ables between the groups. Differences between dichotomous 
variables were evaluated with the chi square test. The calcula-
tions were performed with the SPSS software (SPSS version 12.0, 
Chicago, IL, USA). P values less than 0.05 were considered sig-
nificant.
Ethics statement
The study was approved by the institutional review board of the 
Catholic University of Korea (VCMC07MI066) and the Korea 
Food and Drug Administration (KFDA-483). Each patient pro-
vided written informed consent to participate.Choi KH, et al.  •  Levofloxacin and Rifaximin Based Quadruple Therapy 
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RESULTS
Demographic features
The characteristics of all patients are summarized in Table 1. 
Five out of 300 patients were excluded because of the history of 
H. pylori eradication or recent use of antibiotics (n = 1 in OAC; 
n = 2 in OAL; n = 2 in OAL-R). Eleven patients discontinued treat-
ment because of adverse effects (n = 5 in OAC; n = 3 in OAL; n = 
3 in OAL-R). Follow-up was incomplete in 16 patients (n = 4 in 
OAC; n = 8 in OAL; n = 4 in OAL-R). The reasons for incomplete 
follow-up were emigration, private business or reluctance to par-
ticipate in the clinical trial (Fig. 1).
Eradication rate
H. pylori eradication (intention to treat) was successful in 77/99 
(77.8%) with OAC, 64/98 (65.3%) with OAL and 73/98 (74.5%) 
with OAL-R. Per protocol analyses were: OAC, 77/90 (85.6%); 
OAL, 64/87 (73.6%) and OAL-R, 73/91 (80.2%). The eradication 
rate achieved with the OAL regimen was significantly lower than 
with the standard OAC regimen in the ITT (P = 0.05) and PP anal-
ysis (P = 0.04). The OAL-R regimen was not inferior to the OAC 
regimen (Fig. 2). No differences were found between the OAL 
and the OAL-R regimen (ITT, P = 0.16; PP, P = 0.29).
Adverse effects
No significant differences in patient compliance and frequency 
Table 1. The characteristics of the enrolled patients
Parameters OAC  
(n = 99)
OAL  
(n = 98)
OAL-R  
(n = 98)
P 
value
Sex
Male:female 54:45 58:40 59:39 0.69
Age (yr)   55.6 ± 16.2     55.5 ± 11.1     52.7 ± 12.5 0.32
Height (cm) 162.1 ± 12.9 162.4 ± 8.1 163.5 ± 7.9 0.55
Weight (kg)   63.5 ± 10.2   62.7 ± 9.3     64.0 ± 10.9 0.63
Smoker yes:no 20:79 25:73 24:74 0.65
Alcohol yes:no 31:68 35:63 42:56 0.24
Diagnosis
   Gastric ulcer
   Duodenal ulcer
   Both
   Gastritis
 
58
25
  3
13
 
48
25
  4
21
  
44
29
  2
23
0.15
Poor compliance   5
Diarrhea (2)
Abdominal pain (1)
Nausea (1)
Bitter taste (1)
  3
Diarrhea (1)
Nausea (1)
Itching (1)
  3
Headache (1)
Itching (1)
Facial edema (1)
0.70
Loss of follow up    4   8   4 0.34
Completion of protocol 90 87 91
OAC, omeprazole, amoxicillin, clarithromycin; OAL, omeprazole, amoxicillin, levofloxa-
cin; OAL-R, omeprazole, amoxicillin, levofloxacin, rifaximin. 
%
*P < 0.05 *
*
  OAC  OAL  OAL-R
90
80
70
60
50
40
30
20
10
0
Fig. 2. Eradication rate. The eradication rate achieved with the OAL regimen was signifi-
cantly lower than with the standard OAC regimen in the ITT and PP analysis (P < 0.05). 
OAC, omeprazole amoxicillin clarithromycin; OAL, omeprazole amoxicillin levofloxacin; 
OAL-R, omeprazole amoxicillin levofloxacin rifaximin; ITT, intention-to-treat; PP, per-protocol.
ITT PP
Table 2. Incidence of adverse effects in Helicobacter pylori eradication therapy
Symptoms OAC regimen OAL OAL-R P value
Total (moderate  
   to severe)
50/90  
(29/90)
40/87  
(17/87)
37/91  
(9/91)
0.13 (< 0.01)*
Anorexia 10 (3) 12 (3)   9 (2)  0.71 (0.86)
Nausea 14 (1) 10 (1)   8 (0)  0.37 (0.60)
Change of taste 20 (7)   5 (1)   4 (2) < 0.01* (0.04)*
Dizziness   8 (2)   6 (0)   6 (0)  0.82 (0.14)
Abdominal pain   8 (2)   6 (3)   4 (1)  0.48 (0.57)
Diarrhea   29 (15)   20 (10) 23 (3)   0.35 (0.01)*
Headache   8 (1)   5 (1)   6 (1)  0.69 (0.99)
Skin eruption   6 (2)   5 (3)   5 (2)  0.94 (0.84)
Other   8 (6)
Dry mouth (1)
Itching (2)
Constipation (2)
Edema (1)
Foul odor (1)
  5 (2)
Fatigue (1)
Bloating (1)
  4 (1)
Constipation (1)
 0.44 (0.09)
*, P < 0.05. OAC, omeprazole, amoxicillin, clarithromycin; OAL, omeprazole, amoxi-
cillin, levoflo  xacin; OAL-R, omeprazole, amoxicillin, levofloxacin, rifaximin. 
Fig. 1. Study flow diagram. OAC, omeprazole amoxicillin clarithromycin; OAL, omepra-
zole amoxicillin levofloxacin; OAL-R, omeprazole amoxicillin levofloxacin rifaximin.
Assessment of eligibility (N = 300)
Patents who had H. Pylori associated gastoduodenal disease
Enrollment
OAC (n = 99)
OAC (n = 90)
Randomization and allocation
Completion of protocol
Exclusion (n = 5) - previous history of eradication
  - recent use of antibiotics
• UBT (6 weeks later)
• Interview-check up (compliance/adverse event)
Poor compliance  (OAC, n = 5;  OAL, n = 3;  OAL-R, n = 3) 
Loss of follow-up   (OAC, n = 4;  OAL, n = 8;  OAL-R, n = 4)
OAL (n = 98)
OAL (n = 87)
OAL-R (n = 98)
OAL-R (n = 91)Choi KH, et al.  •  Levofloxacin and Rifaximin Based Quadruple Therapy 
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of adverse effects were found between the groups. The frequen-
cy of moderate to severe adverse effects was significantly higher 
with the OAC regimen (Table 2). Diarrhea was the most com-
mon complaint. Moderate to severe diarrhea was significantly 
low with the OAL-R regimen (Fig. 3). Compliance with the ther-
apy was good for all three regimens; however, 11 patients dis-
continued the treatment. Overall, 11 (1.7%) patients complained 
of diverse adverse effects, including diarrhea (n = 3), abdominal 
pain (n = 1), nausea (n = 2), a bitter taste (n = 1), skin rash/itch-
ing (n = 2), headache (n = 1) and facial edema (n = 1).
DISCUSSION
Over the past 20 yr, standard triple therapy for H. pylori infec-
tion has been adopted worldwide and recommended as first-
line therapy by the Maastricht I and II consensus report (14, 15). 
However, it has limited efficacy, because of adverse effects, poor 
compliance of patients and the development of antibiotic resis-
tance. Especially, primary resistance to metronidazole or clar-
ithromycin significantly affects the efficacy of eradication ther-
apy (16). Resistance to metronidazole is related to prior antibi-
otic exposure, but it does not always lead to treatment failure 
(17). However, primary clarithromycin resistance, which shows 
regional difference, is considered as a strong predictive risk fac-
tor for treatment failure (18). The recent Maastricht III consen-
sus report recommended that the clarithromycin should not be 
used or susceptibility test should be performed where the thresh-
old of this antibiotic was 15%-20% (19). 
  The risk for clarithromycin resistance was associated with pre-
vious treatment with macrolides (erythromycin and azythromy-
cin) that induced cross resistance to clarithromycin (20). In clin-
ical practice, physicians usually prescribe such antibiotics for 
respiratory infections and they are widely used for H. pylori erad-
ication treatment. For example, in France where macrolides have 
been widely used for a long time, the initial rate of H. pylori strains 
resistant to clarithromycin was about 10% (21); however, it has 
increased up to 29.1% (22). Moreover, a recent study reported 
that the number of strains resistant to clarithromycin and met-
ronidazole had gradually increased (23). In Korea, the clarithro-
mycin resistance rate was reported to be below 5%; however, this 
rate increased gradually (24, 25). Now, the resistance rate for 
clarithromycin was reported to be 17.2% (MIC of >1.0 μg/mL) 
(26). For this reason, success rate of standard triple therapy is 
lowered in Korea.
  To reduce antibiotic resistance of H. pylori, the use of antibi-
otics needs to be limited and susceptibility testing performed 
before initiation of the eradication therapy. The role of antibiot-
ic sensitivity testing prior to starting first-line therapy has been 
controversial. There are conflicting results on whether antibiot-
ic sensitivity testing would be an efficient approach to H. pylori 
eradication therapy (26, 27). Therefore, choosing eradication 
regimens other than the standard triple therapy, as first-line 
therapy, might be advisable in areas with a high prevalence of 
primary antibiotic resistance. Rifaximin was reported to be ac-
Fig. 3. Frequency of adverse effects in eradication therapy. (A) No significant differences in frequency of adverse effects were found among the groups. (B) The frequency of 
moderate to severe adverse effects was significantly higher with the OAC regimen. Diarrhea was the most common complaint. Moderate to severe diarrhea was significantly 
low with the OAL-R regimen. OAC, omeprazole amoxicillin clarithromycin; OAL, omeprazole amoxicillin levofloxacin; OAL-R, omeprazole amoxicillin levofloxacin rifaximin.
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tive against H. pylori strains resistant to clarithromycin (9); thus 
suggesting that it might be useful in combination with this drug. 
Moreover, it has a low risk of causing antibiotic resistance, and 
rifaximin can be a good candidate for H. pylori eradication. 
  This study was conducted to assess the efficacy of levofloxa-
cin and rifaximin based therapy in clinical practice with a Kore-
an cohort. Whether rifaximin could provide additional benefit 
for the eradication of H. pylori was assessed. The result showed 
that the levofloxacin and rifaximin based quadruple regimen 
was not inferior to the standard first-line therapy, whereas the 
levofloxacin based regimen showed limited efficacy. It is sur-
prising that the levofloxacin-based triple regimen was inferior 
to the standard first-line therapy. In the past few years, a triple 
therapy including a levofloxacin–amoxycillin combination has 
been proposed for either first-line or rescue therapy regimen to 
cure H. pylori infection (28). This finding could depend on the 
higher prevalence of primary levofloxacin resistance. Unfortu-
nately, the prevalence of primary levofloxacin resistance rate is 
increasing up to 21.5% in Korea (29). Such an increase in the 
bacterial resistance against levofloxacin probably comes from 
treatment of pulmonary or urinary infections with quinolones.
  However, several methodological weaknesses may limit the 
validity of these findings. First, a major limitation of this study 
was the single center collection of data, raising concern about 
the ability to generalize the results. Second, we did not measure 
antibiotic resistance. Third, the CYP2C19 genotypes were not 
considered as a potential influence on the outcome of eradica-
tion therapy. The principal enzyme involved in the metabolism 
of the PPI’s is CYP2C19, and there are inter-individual differenc-
es in the activity of this enzyme (30). A large, multicenter-based 
comparative study is needed to confirm the findings. 
  Antibiotic-associated gastrointestinal adverse effects such as 
diarrhea, nausea, vomiting, bloating, and abdominal pain may 
cause patients to interrupt the prescribed regimen. This can lead 
to bacterial resistance. The frequency and severity of individual 
symptoms during eradication therapy were analyzed in this study. 
The frequency of diarrhea, taste disturbance, and abdominal 
pain were similar in all three groups. Moderate to severe adverse 
effects were more common with the standard therapy. Of note, 
was the significant safety profile of rifaximin. When diarrhea oc-
curs with eradication therapy it is usually transient and self lim-
iting; however, occasionally, severe effects occur. Several cases 
of Clostridium difficile infection have been reported. The results 
of this study showed that diarrhea was the most common com-
plaint during eradication therapy and the most important factor 
associated with drug compliance. The regimen with rifaximin 
had a significantly lower frequency of moderate to severe diar-
rhea. However, it had limited efficacy compared to the standard 
first-line therapy. In the near future, high-dose regimens (400 mg, 
tid) or longer duration (e.g. 10 or 14 days) will be tested with ri-
faximin with the hope of achieving better eradication rates. 
  In summary, the levofloxacin and rifaximin based regimen 
comes up to the standard triple therapy but has limited efficacy 
in a Korean cohort. When rifaximin is added to amoxicillin or 
levofloxacin at a sub-inhibitory concentration, synergistic effect 
on H. pylori eradication therapy is not observed. However, the 
rifaximin containing regimen has an excellent safety profile and 
might have improved efficacy at a full dose of it or in combina-
tion with other antibiotics.
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Efficacy of Levofloxacin and Rifaximin based Quadruple Therapy in Helicobacter pylori 
Associated Gastroduodenal Disease: A Double-Blind, Randomized Controlled Trial
Kang Hyun Choi, Woo Chul Chung, Kang-Moon Lee, Chang Nyol Paik, Eun Jung Kim, Bong Koo Kang, Ju Hyun Oak and Sung Hoon Jung
The standard triple therapy for H. pylori infection, which includes proton pump inhibitor (PPI), amoxicillin and clarithromycin fails 
in up to 20% of patients or even higher in some clinical setting. We aim to determine the efficacy of levofloxacin in Korea. 
Additionally, the combination of rifaximin is studied for its synergistic effects for H. pylori eradication. The levofloxacin and 
rifaximin based regimens come up to the standard triple therapy but had limited efficacy in a Korean cohort. In the process of 
therapy, diarrhea was the most common complaint. The rifaximin containing regimen had a significantly lower frequency of 
moderate to severe diarrhea. In the near future, high-dose regimens (400 mg, tid) or longer duration (e.g. 10 or 14 days) will be 
tested with rifaximin with the hope of achieving better eradication rates.